0J8Z.LSE Illumina Inc.
- Market cap
- -
- P/E
- 49.5x
- P/B
- -
- ROE
- 22.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.
Is 0J8Z.LSE undervalued?
Graham numberThe Graham number of Illumina Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Illumina Inc. fundamental analysis
No fundamental analysis for Illumina Inc. yet.
Illumina Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Illumina Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific gene…
Full company profileIllumina Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Illumina Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.40B | 2.75B | 3.33B | 3.54B | 3.24B | 4.53B | 4.58B | 4.50B | 4.37B | 4.34B | 4.47B |
| Gross Profit | 1.69B | 1.87B | 2.33B | 2.47B | 2.22B | 3.15B | 2.97B | 2.94B | 2.86B | 2.96B | 3.13B |
| Operating Income | 583M | 628M | 883M | 993M | 580M | 286M | 354M | -1.07B | 400M | 983M | 1.05B |
| EBITDA | 735M | 780M | 1.06B | 1.17B | 767M | 747M | 543M | -608M | -725M | 1.36B | 1.33B |
| Net Income | 454M | 725M | 826M | 1.00B | 656M | 762M | -4.40B | -1.16B | -1.22B | 850M | 695M |
| EPS | 3.07 | 4.90 | 5.54 | 6.72 | 4.43 | 5.05 | -28 | -7.35 | -7.69 | 5.45 | 4.51 |
| Balance Sheet | |||||||||||
| Total Assets | 4.28B | 5.26B | 6.96B | 7.32B | 7.59B | 15.2B | 12.3B | 10.1B | 6.30B | 6.64B | 6.81B |
| Total Liabilities | 1.97B | 2.29B | 3.05B | 2.70B | 2.89B | 4.48B | 5.65B | 4.37B | 3.93B | 3.92B | 3.67B |
| Shareholders' Equity | 2.20B | 2.75B | 3.76B | 4.61B | 4.69B | 10.7B | 6.60B | 5.75B | 2.37B | 2.72B | 3.15B |
| Cash & Short-term Investments | 1.56B | 2.15B | 3.51B | 3.41B | 3.47B | 1.34B | 2.04B | 1.05B | 1.22B | 1.63B | 1.34B |
| Total Debt | 1.05B | 1.19B | 2.00B | 1.88B | 1.91B | 2.54B | 3.56B | 2.26B | 2.70B | 2.55B | 2.31B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 687M | 875M | 1.14B | 1.05B | 1.08B | 545M | 392M | 478M | 837M | 1.08B | 1.20B |
| Capital Expenditure | 271M | 312M | 296M | 209M | 189M | 208M | 466M | 195M | 128M | 148M | 535M |
| Free Cash Flow | 416M | 563M | 846M | 842M | 891M | 337M | -74.0M | 283M | 709M | 931M | - |
| Ratios | |||||||||||
| ROE | 20.7% | 26.4% | 22.0% | 21.7% | 14.0% | 7.1% | -66.7% | -20.2% | -51.5% | 31.2% | 22.1% |
| ROA | 10.6% | 13.8% | 11.9% | 13.7% | 8.6% | 5.0% | -35.9% | -11.5% | -19.4% | 12.8% | 10.2% |
| Net Profit Margin | 18.9% | 26.3% | 24.8% | 28.3% | 20.3% | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% | 15.5% |
| Debt to Equity | 0.48x | 0.43x | 0.53x | 0.41x | 0.41x | 0.24x | 0.54x | 0.39x | 1.14x | 0.94x | 0.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Illumina Inc. dividends
Illumina Inc. has not paid dividends in the last 9 fiscal years.
Who owns Illumina Inc.
- Insiders 0.21%
- Institutions 99.79%
- Public & others 0.00%
- Free float 151M
Illumina Inc. company profile
- Company name
- Illumina Inc.
- Ticker
- 0J8Z.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 8,600
- Fiscal year end
- January
- Address
- 5200 Illumina Way, San Diego, CA, United States, 92122
- Phone
- 858 202 4500
- Website
- illumina.com
About Illumina Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina Inc. management
10- Mr. Jacob Thaysen Ph.D.CEO, President & Director · born 1975
- Mr. Ankur Dhingra CPAChief Financial Officer · born 1976
- Mr. Kevin Carl PegelsChief of Global Operations · born 1968
- Dr. Steven Barnard Ph.D.Chief Technology Officer · born 1961
- Mr. Scott EricksenVP & Chief Accounting Officer · born 1973
- Mr. Mark FieldChief Information Officer · born 1971
- Mr. Conor Noel McNamara C.F.A.VP of Investor Relations
- Ms. Julie Ann Coletti J.D.Chief Legal Officer · born 1968
- Mr. Jakob WedelChief Strategy & Corporate Development Officer · born 1972
- Ms. Patricia LeckmanSenior VP & Chief People Officer · born 1964